Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.
Lichterfeld M, Gandhi RT, Simmons RP, Flynn T, Sbrolla A, Yu XG, Basgoz N, Mui S, Williams K, Streeck H, Burgett-Yandow N, Roy G, Janssens M, Pedneault L, Vandepapelière P, Koutsoukos M, Demoitié MA, Bourguignon P, McNally L, Voss G, Altfeld M. Lichterfeld M, et al. Among authors: demoitie ma. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):1-9. doi: 10.1097/QAI.0b013e3182373b77. J Acquir Immune Defic Syndr. 2012. PMID: 21963936 Free PMC article. Clinical Trial.
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, Collard A, Demoitié MA, Voss G, Leroux-Roels G, McNally L. Van Braeckel E, et al. Among authors: demoitie ma. Clin Infect Dis. 2011 Feb 15;52(4):522-31. doi: 10.1093/cid/ciq160. Epub 2011 Jan 5. Clin Infect Dis. 2011. PMID: 21208909 Free PMC article. Clinical Trial.
Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.
Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, Moris P, De Kock E, Clement F, Dubois MC, Koutsoukos M, Demoitié MA, Cohen J, Ballou WR. Leroux-Roels I, et al. Among authors: demoitie ma. Clin Vaccine Immunol. 2010 Nov;17(11):1763-71. doi: 10.1128/CVI.00133-10. Epub 2010 Sep 22. Clin Vaccine Immunol. 2010. PMID: 20861328 Free PMC article. Clinical Trial.
The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.
Spertini F, Audran R, Lurati F, Ofori-Anyinam O, Zysset F, Vandepapelière P, Moris P, Demoitié MA, Mettens P, Vinals C, Vastiau I, Jongert E, Cohen J, Ballou WR. Spertini F, et al. Among authors: demoitie ma. Tuberculosis (Edinb). 2013 Mar;93(2):179-88. doi: 10.1016/j.tube.2012.10.011. Epub 2012 Dec 5. Tuberculosis (Edinb). 2013. PMID: 23219236 Clinical Trial.
A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.
Montoya J, Solon JA, Cunanan SR, Acosta L, Bollaerts A, Moris P, Janssens M, Jongert E, Demoitié MA, Mettens P, Gatchalian S, Vinals C, Cohen J, Ofori-Anyinam O. Montoya J, et al. Among authors: demoitie ma. J Clin Immunol. 2013 Nov;33(8):1360-75. doi: 10.1007/s10875-013-9949-3. Epub 2013 Oct 20. J Clin Immunol. 2013. PMID: 24142232 Free PMC article. Clinical Trial.
Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.
Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitié MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori-Anyinam O, Hanekom WA. Day CL, et al. Among authors: demoitie ma. Am J Respir Crit Care Med. 2013 Aug 15;188(4):492-502. doi: 10.1164/rccm.201208-1385OC. Am J Respir Crit Care Med. 2013. PMID: 23306546 Free PMC article. Clinical Trial.
Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).
Agnandji ST, Fendel R, Mestré M, Janssens M, Vekemans J, Held J, Gnansounou F, Haertle S, von Glasenapp I, Oyakhirome S, Mewono L, Moris P, Lievens M, Demoitie MA, Dubois PM, Villafana T, Jongert E, Olivier A, Cohen J, Esen M, Kremsner PG, Lell B, Mordmüller B. Agnandji ST, et al. Among authors: demoitie ma. PLoS One. 2011 Apr 11;6(4):e18559. doi: 10.1371/journal.pone.0018559. PLoS One. 2011. PMID: 21494604 Free PMC article. Clinical Trial.
Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.
Gillard P, Yang PC, Danilovits M, Su WJ, Cheng SL, Pehme L, Bollaerts A, Jongert E, Moris P, Ofori-Anyinam O, Demoitié MA, Castro M. Gillard P, et al. Among authors: demoitie ma. Tuberculosis (Edinb). 2016 Sep;100:118-127. doi: 10.1016/j.tube.2016.07.005. Epub 2016 Jul 21. Tuberculosis (Edinb). 2016. PMID: 27553419 Free article. Clinical Trial.
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
Thacher EG, Cavassini M, Audran R, Thierry AC, Bollaerts A, Cohen J, Demoitié MA, Ejigu D, Mettens P, Moris P, Ofori-Anyinam O, Spertini F. Thacher EG, et al. Among authors: demoitie ma. AIDS. 2014 Jul 31;28(12):1769-81. doi: 10.1097/QAD.0000000000000343. AIDS. 2014. PMID: 24911353 Clinical Trial.
45 results